bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Authors: Feng Jia-Hua , Nakagawa-Goto Kyoko , Lee Kuo-Hsiung , Shyur Lie-Fen
Published: April 2023

Experimental design, body weight and organ index of A375 xenograft study
Supplementary figure S3 from Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Authors: Esfandiari Arman , Hawthorne Thomas A. , Nakjang Sirintra , Lunec John
Published: April 2023

Supplementary figure S3: A) The ratios pp53Ser15 band: total p53 band optical density values (OD) in Figure 4F (Left) and 3D (Right) quantified using Imagej software. B) Western blot showing changes in pp53Ser15, MDM2, and p21WAF1 expression 12 hours after different concentrations of wild-type p53 (Wt), p53 mutants Ser15Ala (S15A) and Ser15Asp (S15D) ectopic expression in HCT116-/- cells. C) The quantification of p21WAF1 and MDM2 band OD values based on the last three lanes in Supplementary figure S3B and Figure 4F. The OD values were normalised to the optical density value calculated from the same area in the pcDNA3.1 track on each image.
Supplementary Figures S1-S42, Supplementary Tables S1-S2, and Supplementary Materials and Methods from Novel Indole-based Tambjamine-Analogues Induce Apoptotic Lung Cancer Cell Death through p38 Mitogen-Activated Protein Kinase Activation
Authors: Manuel-Manresa Pilar , Korrodi-Gregório Luís , Hernando Elsa , Villanueva Alberto , Martínez-García David , Rodilla Ananda M. , Ramos Ricard , Fardilha Margarida , Moya Juan , Quesada Roberto , Soto-Cerrato Vanessa , Pérez-Tomás Ricardo
Published: April 2023

Supplementary Figures: Figure S1. Set of tambjamine analogues investigated; Figure S2. General reaction scheme; Figure S3. 1H NMR (DMSO-d6) of compound 3.HCl; Figure S4. 13C (DMSO-d6) of compound 3.HCl; Figure S5. HRMS (EI) of compound 3; Figure S6. 1H NMR (DMSO-d6) of compound 4.HCl; Figure S7. 13C (DMSO-d6) of compound 4.HCl; Figure S8. 13C dept (DMSO-d6) of compound 4.HCl; Figure S9. HRMS (EI) of compound 4.; Figure S10. 1H NMR (CDCl3) of compound 5.HCl; Figure S11. 13C NMR (CDCl3) of compound 5.HCl; Figure S12. 13C dept NMR (CDCl3) of compound 5.HCl; Figure S13. HRMS (EI) of compound 5.; Figure S14. 1H NMR (CDCl3) of compound 6.HCl; Figure S15. 13C NMR (CDCl3) of compound 6.HCl; Figure S16. HRMS (EI) of compound 6.; Figure S17. 1H NMR (CDCl3) of compound 7.HCl; Figure S18. 13C NMR (CDCl3) of compound 7.HCl; Figure S19. 13C dept NMR (CDCl3) of compound 7.HCl; Figure S20. HRMS (EI) of compound 7.; Figure S21. 1H NMR (CDCl3) of compound 8.HCl; Figure S22. 13C NMR (CDCl3) of compound 8.HCl; Figure S23. 13C dept NMR (CDCl3) of compound 8.HCl; Figure S24. HRMS (EI) of compound 8.; Figure S25. 1H NMR (CDCl3) of compound 9.HCl; Figure S26. 13C NMR (CDCl3) of compound 9.HCl; Figure S27. 13C dept NMR (CDCl3) of compound 9.HCl; Figure S28. HRMS (EI) of compound 9.; Figure S29. 1H NMR (CDCl3) of compound 10.HCl; Figure S30. 13C NMR (CDCl3) of compound 10.HCl; Figure S31. 13C dept NMR (CDCl3) of compound 10.HCl; Figure S32. HRMS (EI) of compound 10; Figure S33. 1H NMR (CDCl3) of compound 11.HOAc; Figure S34. 13C NMR (CDCl3) of compound 11.HOAc; Figure S35. 13C dept NMR (CDCl3) of compound 11.HOAc; Figure S36. HRMS (EI) of compound 11; Figure S37. Dose response curves in A549, DMS53, SW900 and H460 cells; Figure S38. Dose response curves in human lung tumor-derived primay cultures; Figure S39. Array validation using TaqMan gene expression assays; Figure S40. Cell cycle assay by flow cytometry; Figure S41. Western blot of apoptotic markers in the DMS53 cell line; Figure S42. Body weight recording; Supplementary Tables: Table S1. Applied biosystem probes list used for the TaqMan gene expression assays; Table S2. List of altered genes in the cancer drug targets QIAGEN RT2 Profiler Array for the SW900 cell line; Supplementary Materials and Methods: Synthesis and characterization; Cell viability; TaqMan assays; Gene expression; Cell cycle; Western blot; Mice weight.
Supplementary Figure 1 from Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma
Authors: Du Zhiqiang , Caenepeel Sean , Shen Yuqing , Rex Karen , Zhang Yanni , He Ying , Tang En-Tzu , Wang Ouhong , Zhong Wenge , Zhou Hui , Huang Jacqueline , Huang Eric , Hu Liaoyuan , Coxon Angela , Zhang Mingqiang
Published: April 2023

Western blot analysis in responsive PDX model (LI0612) after 14 days treatment. Total and phosphorylated levels of the indicated proteins were evaluated to assess the effects of AMG 337 on MET signaling. Five to twelve PDX samples were processed for each group.
Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

Correlation between marker expression intensity and sample collection year. Corr. = correlation coefficient, A.U. = arbitrary unites.
Supplemental table S3 from The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Authors: Zhang Hui , Patel Atish , Wang Yi-Jun , Zhang Yun-Kai , Kathawala Rishil J. , Qiu Long-Hui , Patel Bhargav A. , Huang Li-Hua , Shukla Suneet , Yang Dong-Hua , Ambudkar Suresh V. , Fu Li-Wu , Chen Zhe-Sheng
Published: April 2023

Ibrutinib does not significantly sensitizes ABCG2-overexpressing cells to mitoxantrone.
Supplemental table S2 from The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Authors: Zhang Hui , Patel Atish , Wang Yi-Jun , Zhang Yun-Kai , Kathawala Rishil J. , Qiu Long-Hui , Patel Bhargav A. , Huang Li-Hua , Shukla Suneet , Yang Dong-Hua , Ambudkar Suresh V. , Fu Li-Wu , Chen Zhe-Sheng
Published: April 2023

Ibrutinib significantly sensitizes ABCC10-overexpressing cells to vincristine.
Supplementary Figure 1. Hierarchical clustering of response to single agent treatments. from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

Hierarchical clustering was performed on the response data across the cell line panel to the single agent treatments. Drugs with similar mechanisms of action clustered together.
Supplementary figures from Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia
Authors: Ding Jixin , Fishel Melissa L. , Reed April M. , McAdams Erin , Czader Magdalena B. , Cardoso Angelo A. , Kelley Mark R.
Published: April 2023

Suppl Fig S1-S4
Suppl Fig legends and Table from Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia
Authors: Ding Jixin , Fishel Melissa L. , Reed April M. , McAdams Erin , Czader Magdalena B. , Cardoso Angelo A. , Kelley Mark R.
Published: April 2023

Supplementary figure legends and table
Supplementary Data-Response Legends from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

Legend for raw response data
Supplementary Methods and Materials from Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer
Authors: Chen Long , Li Jie , Farah Elia , Sarkar Sukumar , Ahmad Nihal , Gupta Sanjay , Larner James , Liu Xiaoqi
Published: April 2023

Structure of drugs used in this manuscript
Supplementary Figure S2 from Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer
Authors: Patterson Andrea M. , Kaabinejadian Saghar , McMurtrey Curtis P. , Bardet Wilfried , Jackson Ken W. , Zuna Rosemary E. , Husain Sanam , Adams Gregory P. , MacDonald Glen , Dillon Rachelle L. , Ames Harold , Buchli Rico , Hawkins Oriana E. , Weidanz Jon A. , Hildebrand William H.
Published: April 2023

RL21A targets MIF19-27 in other HLA-A*02:0x alleles.
Supplementary Tables S1 through S3 and Supplementary Figures S1 and S2 from ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
Authors: Nakanishi Yoshito , Mizuno Hideaki , Sase Hitoshi , Fujii Toshihiko , Sakata Kiyoaki , Akiyama Nukinori , Aoki Yuko , Aoki Masahiro , Ishii Nobuya
Published: April 2023

Supplementary Table S1 Genetic status information of cancer cell lines Supplementary Table S2 List of probe that is significantly modulated by CH5183284/Debio 1347 Supplementary Table S3 In vivo efficacy data of CH5183284/Debio 1347 Supplementary Figure S1. MAPK pathway suppression by CH5183284/Debio 1347 in FGFR genetically altered cancer cell lines Supplementary Figure S2. Modulation of DUSP6 expression in FGFR inhibitor sensitive cancer cell lines
Supplementary Figure S6 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Concentration of C4.4A-ADC metabolite BAY 1136309 in NCI-H292 tumors in mice after administration of C4.4A-ADC.
Supplemental Table 1 from Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Authors: Peng Sheng-Bin , Zhang Xiaoyi , Paul Donald , Kays Lisa M. , Gough Wendy , Stewart Julie , Uhlik Mark T. , Chen Qi , Hui Yu-Hua , Zamek-Gliszczynski Maciej J. , Wijsman John A. , Credille Kelly M. , Yan Liang Zeng
Published: April 2023

Supplemental Table 1: Activities of LY2510924.acetate in ligand binding assays of selected chemokine receptors and other GPCRs
Supplementary Figures 1 through 7 from Lappaol F, a Novel Anticancer Agent Isolated from Plant Arctium Lappa L.
Authors: Sun Qing , Liu Kanglun , Shen Xiaoling , Jin Weixin , Jiang Lingyan , Saeed Sheikh M. , Hu Yingjie , Huang Ying
Published: April 2023

PDF - 430K, Supplementary Fig. S1 UV Spectrum of Lappaol F Supplementary Fig. S2 1H NMR Spectrum of Lappaol F Supplementary Fig. S3 13C NMR Spectrum of Lappaol F. Supplementary Fig. S4 ESI MS Spectrum of Lappaol F Supplentary Fig S5 Purity of Lappaol F determined by HPLC Supplementary Fig. S6 Cytotoxic effect of Lappaol F on various tumor cell lines. Supplementary Fig. S7 p53 expression in MCF-7 and RKO cells with or without Lappaol F treatment.
Supplementary Figure 4 from Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Authors: Seystahl Katharina , Papachristodoulou Alexandros , Burghardt Isabel , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick , Weller Michael
Published: April 2023

Validation of TGF-β antibodies
Supplementary Figure 1 from Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Authors: Seystahl Katharina , Papachristodoulou Alexandros , Burghardt Isabel , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick , Weller Michael
Published: April 2023

Structure of ISTH2020 and ISTH2023
Figure legends Supplementary Figures from Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Authors: Seystahl Katharina , Papachristodoulou Alexandros , Burghardt Isabel , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick , Weller Michael
Published: April 2023

Figure legends Supplementary Figures
Supplementary Table 5 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Authors: Ang Joo Ern , Pandher Rupinder , Ang Joo Chew , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de Haven Brandon Alexis , Baird Richard D. , Friedman Lori , Derynck Mika , Vanhaesebroeck Bart , Eccles Suzanne A. , Kaye Stan B. , Workman Paul , de Bono Johann S. , Raynaud Florence I.
Published: April 2023

Changes in plasma metabolites across timepoints by patient/sample.
Supplementary Table 4 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Authors: Ang Joo Ern , Pandher Rupinder , Ang Joo Chew , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de Haven Brandon Alexis , Baird Richard D. , Friedman Lori , Derynck Mika , Vanhaesebroeck Bart , Eccles Suzanne A. , Kaye Stan B. , Workman Paul , de Bono Johann S. , Raynaud Florence I.
Published: April 2023

Changes in candidate plasma metabolite pharmacodynamic biomarker concentrations over first 2 weeks in 17 patients treated with {greater than or equal to}330 mg once-daily of pictilisib. Cells with p-values <0.05 are shaded dark grey and those with p-values <0.10 and {greater than or equal to}0.05 are shaded light grey.
Supplementary Figure Legends from FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
Authors: McLaughlin Kylie A. , Nemeth Zsuzsanna , Bradley Conor A. , Humphreys Luke , Stasik Izabela , Fenning Catherine , Majkut Joanna , Higgins Catherine , Crawford Nyree , Holohan Caitriona , Johnston Patrick G. , Harrison Timothy , Hanna Gerard G. , Butterworth Karl T. , Prise Kevin M. , Longley Daniel B.
Published: April 2023

Figure legends for Supplementary Figures
Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Authors: Murone Maximilien , Vaslin Chessex Anne , Attinger Antoine , Ramachandra Raghuveer , Shetty Shankar J. , Daginakatte Girish , Sengupta Saumitra , Marappan Sivapriya , Dhodheri Samiulla , Rigotti Stefania , Bachhav Yogeshwar , Brienza Silvano , Traxler Peter , Lang Marc , Aguet Michel , Zoete Vincent , Michielin Olivier , Nicholas Courtney , Johnson Faye M. , Ramachandra Murali , McAllister Andres
Published: April 2023

Suppl. Table 1. Binding mode of Debio 0617B to ABL. Suppl. Table 2. Physico-chemical and early ADME profile of Debio 0617B. Suppl. Table 3. Debio 0617B activity on a panel of 21 cancer cell lines. Suppl. Table 4. PK/PD Profile of Debio 0617B in mice with A549 tumors.
Supplementary Figures 1-3 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Authors: Murone Maximilien , Vaslin Chessex Anne , Attinger Antoine , Ramachandra Raghuveer , Shetty Shankar J. , Daginakatte Girish , Sengupta Saumitra , Marappan Sivapriya , Dhodheri Samiulla , Rigotti Stefania , Bachhav Yogeshwar , Brienza Silvano , Traxler Peter , Lang Marc , Aguet Michel , Zoete Vincent , Michielin Olivier , Nicholas Courtney , Johnson Faye M. , Ramachandra Murali , McAllister Andres
Published: April 2023

Suppl. Fig. 1 Characterization for pSTAT3 activation in cancer cell lines responding to Debio 0617B in vitro by Western blot analysis.Suppl. Fig. 2 A-C. Efficacy studies with Debio 0617B in A549, A2058 and A431 models: body weight loss/gain (%). Suppl. Fig. 3A. Histopathology of primary tumors in the 4T1 mammary tumor model. 3B. Efficacy of Debio 0617B in the 4T1 neoadjuvant mammary tumor model: body weight loss/gain (%).
Supplementary Figure 2 from FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
Authors: McLaughlin Kylie A. , Nemeth Zsuzsanna , Bradley Conor A. , Humphreys Luke , Stasik Izabela , Fenning Catherine , Majkut Joanna , Higgins Catherine , Crawford Nyree , Holohan Caitriona , Johnston Patrick G. , Harrison Timothy , Hanna Gerard G. , Butterworth Karl T. , Prise Kevin M. , Longley Daniel B.
Published: April 2023

Caspase-8 dependent apoptosis induced by IR
Supplementary Figure Legends from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Authors: Gordon Michael A. , D'Amato Nicholas C. , Gu Haihua , Babbs Beatrice , Wulfkuhle Julia , Petricoin Emanuel F. , Gallagher Isela , Dong Ting , Torkko Kathleen , Liu Bolin , Elias Anthony , Richer Jennifer K.
Published: April 2023

Figure legends for supplementary data
Supplemental Figure 1 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Additional cell-based DSB repair assay optimization studies in preparation for high-throughput screening.
Supplementary Tables S1-S4 from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Authors: Huang Fei , Chang Han , Greer Ann , Hillerman Stephen , Reeves Karen A. , Hurlburt Warren , Cogswell John , Patel Dharmesh , Qi Zhenhao , Fairchild Craig , Ryseck Rolf-Peter , Wong Tai W. , Finckenstein Friedrich G. , Jackson Jeffrey , Carboni Joan M.
Published: April 2023

Supplementary Tables S1-S4. Supplementary Table S1: Association of gene mutations, IRS2 copy number gain, and gene expression level with in vitro sensitivity to BMS-754807 in 60 CRC cell lines. Supplementary Table S2: The relationship between KRAS, BRAF and PIK3CA mutation status and the sensitivity of BMS-754807 in 60 CRC cell lines. Supplementary Table S3: Statistical analyses identified CNV of 197 genes located on chromosome 13 significantly associated with in vitro sensitivity to BMS-754807 in 60 CRC cell lines. Supplementary Table S4: Data mining indicate IRS2 CNG is more prevalent in CRC than in other tumor types.
Supplemental Table 3 from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Authors: Lin Xiaoyu , Huang Xiaoli , Uziel Tamar , Hessler Paul , Albert Daniel H. , Roberts-Rapp Lisa A. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Expression change of 25 potential BET inhibitor responsive genes in NCI-H1299, MiaPaCa-2, and MX-1 cells treated with DMSO or 0.5 μM MS417 for 6 hours.
Supplementary Material and Methods from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Authors: Huang Fei , Chang Han , Greer Ann , Hillerman Stephen , Reeves Karen A. , Hurlburt Warren , Cogswell John , Patel Dharmesh , Qi Zhenhao , Fairchild Craig , Ryseck Rolf-Peter , Wong Tai W. , Finckenstein Friedrich G. , Jackson Jeffrey , Carboni Joan M.
Published: April 2023

Material and Methods
Supplemental Table 1 from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Authors: Lin Xiaoyu , Huang Xiaoli , Uziel Tamar , Hessler Paul , Albert Daniel H. , Roberts-Rapp Lisa A. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

290 genes that were modulated by MS417 in both NCI-H1299 and MiaPaCa-2 cells.
Supplementary Table and Supplementary Figures 1 through 4 from Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
Authors: Maede Yuko , Shimizu Hiroyasu , Fukushima Toru , Kogame Toshiaki , Nakamura Terukazu , Miki Tsuneharu , Takeda Shunichi , Pommier Yves , Murai Junko
Published: April 2023

PDF - 7482KB, Supplementary Table 1. DT40 isogenic mutant cell lines used in this study. Cell lines are ordered as in Figure 1. Supplementary Figure 1. Generation of the ATG5-deficient DT40 cells. Supplementary Figure 2. Linearity between cells per well and luminescent signal. Supplementary Figure 3. Representative survival curves and corresponding cell cycle analyses. Supplementary Figure 4. Sensitivity profile of paclitaxel (Taxol) in the DT40 repair panel. Data are plotted as in Figure 1. References to Supplementary Table 1.
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Authors: Ganesh Shanthi , Koser Martin L. , Cyr Wendy A. , Chopda Girish R. , Tao Junyan , Shui Xue , Ying Bo , Chen Dongyu , Pandya Purva , Chipumuro Edmond , Siddiquee Zakir , Craig Kevin , Lai Chengjung , Dudek Henryk , Monga Satdarshan P. , Wang Weimin , Brown Bob D. , Abrams Marc T.
Published: April 2023

supplemental figure legends
Supplemental Table 2 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Authors: Perera Timothy P.S. , Jovcheva Eleonora , Mevellec Laurence , Vialard Jorge , De Lange Desiree , Verhulst Tinne , Paulussen Caroline , Van De Ven Kelly , King Peter , Freyne Eddy , Rees David C. , Squires Matthew , Saxty Gordon , Page Martin , Murray Christopher W. , Gilissen Ron , Ward George , Thompson Neil T. , Newell David R. , Cheng Na , Xie Liang , Yang Jennifer , Platero Suso J. , Karkera Jayaprakash D. , Moy Christopher , Angibaud Patrick , Laquerre Sylvie , Lorenzi Matthew V.
Published: April 2023

Inhibitory activity of Brivanib and JNJ-42756943 in kinase (top) and BaF3 kinase dependent proliferation (bottom) assays and ratio of FGFRs/VEGFR2 activities.
Supplementary Figure S1 from Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Authors: Ilmer Matthias , Garnier Agnès , Vykoukal Jody , Alt Eckhard , von Schweinitz Dietrich , Kappler Roland , Berger Michael
Published: April 2023

(A) Heat map of unchanged proteins that were analyzed by RPPA. The analysis is represented similar to Fig. 1B.
Supplementary Figure 1 from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Authors: LaBonte Melissa J. , Yang Dongyun , Zhang Wu , Wilson Peter M. , Nagarwala Yasir M. , Koch Kevin M. , Briner Colleen , Kaneko Tomomi , Rha Sun-Young , Gladkov Oleg , Urba Susan G. , Sakaeva Dina , Pishvaian Michael J. , Hsieh Ruey-Kuen , Lee Wei-Ping , Lenz Heinz-Josef
Published: April 2023

Waterfall plot of maximum tumor shrinkage from baseline including (or with evaluable) unconfirmed response.
Supplemental Figure S5 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Validation of TMD231 cells transduced with E2-Crimson fluorescent protein in vitro and in vivo for sensitive detection of primary tumor burden.
Supplementary Figure 3 from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

Stat3 expression and proliferation studies upon genetic and pharmacological modification of NFATc2 and GSK-3Î²
Supplementary Materials and Methods, Tables S1 through S3 and Figures S1 and S2 from BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis
Authors: Sanderson Michael P. , Apgar Joshua , Garin-Chesa Pilar , Hofmann Marco H. , Kessler Dirk , Quant Jens , Savchenko Alexander , Schaaf Otmar , Treu Matthias , Tye Heather , Zahn Stephan K. , Zoephel Andreas , Haaksma Eric , Adolf Günther R. , Kraut Norbert
Published: April 2023

Supplementary Materials and Methods, Tables S1 through S3 and Figures S1 and S2 - Supplementary Materials and Methods: The sources, application and dilution of the antibodies used for Western blotting (WB) and immunohistochemical (IHC) analyses in this study are listed. Supplementary Tables: The supplementary tables demonstrate the data and statistics from x-ray co-crystallization experiments with BI 885578 and the human INSR kinase domain (Tables S1 and S2) and the kinase selectivity of BI 885578 on a large panel of human kinases (Table S3). Supplementary Figures: The supplementary figures demonstrate the efficacy and tolerability of BI 885578 in the CL-14 colon cancer xenograft model (Figure S1) and the PD effects of BI 885578 on the phosphorylation of the IGF1R and INSR in GEO tumors (Figure S2).
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 4 from Proteomics of Cancer Cell Lines Resistant to Microtubule-Stabilizing Agents
Authors: Albrethsen Jakob , Angeletti Ruth H. , Horwitz Susan Band , Yang Chia-Ping Huang
Published: April 2023

PDF - 489K, Table S1. Antibodies for Western Blot Analyses. Table S2. Identification of proteins differentially expressed in drug-sensitive and -resistant cells. Fig. S1. Expression levels of stathmin, Ser16-P-stathmin (A) and galectin-1 (B) in drug-sensitive MDA231 and Taxol-resistant K20T cells. Fig. S2. Expression levels of CLIC1, Ezrin and NM23-H1 in drug-resistant A549 and Hey cells. Fig. S3. Suppression of galectin-1 expression in drug-resistant cells. Fig. S4. Suppression of galectin-1 expression increased drug sensitivity in both drug-sensitive and drug-resistant Hey cells.
Supplementary Methods and Supplementary Figures S2-S6 from Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma
Authors: Lescarbeau Rebecca S. , Lei Liang , Bakken Katrina K. , Sims Peter A. , Sarkaria Jann N. , Canoll Peter , White Forest M.
Published: April 2023

Supplementary Methods: Detailed decryption of all methods in the manuscript. Supplementary Figure S2. Heatmap of the 125 phosphopeptides quantified in the first tumor cohort and the normal brain tissues. Supplementary Figure S3. Heatmap of the 78 phosphopeptides quantified in the second tumor cohort and the normal brain tissues. Supplementary Figure S4. Immunoblots to characterize primary murine cell lines and CDK1 phosphorylation. Supplementary Figure S5. DNA damage and apoptosis in murine primary GBM cells. Supplementary Figure S6. Apoptosis and rescue of MGPP7 murine cells.
Supplementary Figure 1 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 86KB, Construction maps for the pIFP1.4-HREmsVEGFR2 and pHREmsVEGFR2 vector,
Suppementary methods and figures from IL4 Receptor–Targeted Proapoptotic Peptide Blocks Tumor Growth and Metastasis by Enhancing Antitumor Immunity
Authors: Vadevoo Sri Murugan Poongkavithai , Kim Jung-Eun , Gunassekaran Gowri Rangaswamy , Jung Hyun-Kyung , Chi Lianhua , Kim Dong Eon , Lee Seung-Hyo , Im Sin-Hyeog , Lee Byungheon
Published: April 2023

Suppementary methods and figures
Supplementary Figure 1 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

The chemical structure and molecular weight of BPR1J373
Supplementary Figures and Tables from Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma
Authors: Qin Yong , Roszik Jason , Chattopadhyay Chandrani , Hashimoto Yuuri , Liu Chengwen , Cooper Zachary A. , Wargo Jennifer A. , Hwu Patrick , Ekmekcioglu Suhendan , Grimm Elizabeth A.
Published: April 2023

Figure S1. Chemical Structure of MSC2156119J (Tepotinib, EMD 1214063); Figure S2. Morphology of melanoma cell 2D ambient air cultures and spheroids; Figure S3. The immunofluorescent staining of DAPI and LOX-1 in A375 2D ambient air cultures; Figure S4. The immunofluorescent staining of LOX-1 in MEL1617 3D spheroids on day 3 and 8 of cultures; Figure S5. The human phospho-kinase antibody array of 451Lu spheroids and 2D ambient air cultures; Figure S6. The human phospho-kinase antibody array of A375 spheroids and 2D ambient air cultures; Figure S7. Effect of PLX4032 on BRAF-ERK pathway in melanoma cells under hypoxic conditions. Supplementary Table S1: Primers for RT-PCR and Real-time PCR; Supplementary Table S2: Patient Characteristics; Supplementary Table S3: List of cutaneous melanoma cell lines in CCLE project
Supplementary Figure 2 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Authors: Cornet Sébastien , Mathé Doriane , Chettab Kamel , Evesque Anne , Matera Eva-Laure , Trédan Olivier , Dumontet Charles
Published: April 2023

The tumor growth inhibition (TGI) was calculated on day 59 and 69 for untreated group and treated groups, respectively. The control group was sacrificed at day 59 as the tumor reached the maximum tolerated tumor size (2000 mm3) and the treated groups were maintained until day 69. In this preliminary experiment we demonstrated a potentiation of rituximab antitumor activity and extended mice survival when co-injected with pegfilgrastim. The results are reported and displayed as the mean {plus minus} SEM of six mice per group
Suuplementary Figure S3: Combined treatment with OBP-801 and celecoxib induces binding of caspase-8 to DR5, and Bim expression in bladder cancer cells. from A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
Authors: Toriyama Seijiro , Horinaka Mano , Yasuda Shusuke , Taniguchi Tomoyuki , Aono Yuichi , Takamura Toshiya , Morioka Yukako , Miki Tsuneharu , Ukimura Osamu , Sakai Toshiyuki
Published: April 2023

A. T24 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 24 h. Cell lysates were subjected to immunoprecipitation with anti-DR5 antibody or an isotype control. Input cell lysates and anti-DR5 immunoprecipitates were analyzed by Western blotting using caspase-8- and DR5-specific antibodies. No proteins were immunoprecipitated using a control isotype-specific antibody. GAPDH was a loading control. B, C. T24 cells or UM-UC-11 cells were transfected with 20 nmol/L or 5 nmol/L Bim siRNA, or NC siRNA. After 24 h, the cells were incubated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h or 72 h. Western blotting of Bim was performed. GAPDH was a loading control. Sub-G1 populations were analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; *, P<0.05, **, P<0.01**.
Supplementary Figure S4: The combination induces apoptosis in a TRAIL-independent manner in UM-UC-11 cells. from A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
Authors: Toriyama Seijiro , Horinaka Mano , Yasuda Shusuke , Taniguchi Tomoyuki , Aono Yuichi , Takamura Toshiya , Morioka Yukako , Miki Tsuneharu , Ukimura Osamu , Sakai Toshiyuki
Published: April 2023

A. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 72 h. Quantitative real-time RT-PCR of TRAIL mRNA was performed. The internal control was β2MG. Values show fold change in TRAIL mRNA expression compared with control (DMSO treatment). Data represent the means of triplicates with SD. B. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib with or without DR5/Fc chimera for 72 h. Sub-G1 populations were analyzed by flow cytometry. C. UM-UC-11 cells were treated with the indicated concentrations of TRAIL or PBS, followed by the treatment with OBP-801 and/or celecoxib at the indicated concentrations. After incubation for 96 h, cell counts were assessed by CCK-8 assay. Columns, means of triplicate data; bars, SD; **, P<0.01. D. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib with or without TRAIL for 72 h. Sub-G1 populations were analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; **, P<0.01.
Table S1 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Table S1 provides results from the whole-genome analysis of the INS-1E cell line.
Figure S6 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

A, Telomerase activity in mouse normal brain, orthotopic PDX DIPG tumor, and patient-derived DIPG-1 cells (CCHMC-DIPG-1), along with negative and positive controls for TRAP assay. IC, indicates internal control. Telomerase products are indicated. B, Telomere FISH-IF images of orthotopic DIPG tumor (PDX) and the matched normal mouse brain. TIFs (yellow) are indicated by white arrows, telomeres (TelC; red) and 53BP1 (green). DAPI (blue) indicates nucleus staining. The two images are from the brain of the same mouse. Of note, mouse telomeres are longer than human, hence the strong telomere signals (in red) in mouse brain relative to human DIPG tumor.
Supplementary Data (UNMARKED) from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

This file gathers all supplementary data (material and methods, supplementary figures and table)
Figure S5 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

Survival probability of 6-thio-dG treated mice with MB004 tumors at a volume of 1500 mm3. Average values of 6 mice per group have been considered and significance between two groups is indicated by P-value, **, P<0.01.
Figure S7 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S7 shows that the β-cell mass of xenografted mice is not affected by treatment with streptozotocin or mTOR inhibitors.
Supplemental Tables S1-S5 and Figures S1-S5 from Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients
Authors: Livingston J. Andrew , Wang Wei-Lien , Tsai Jen-Wei , Lazar Alexander J. , Leung Cheuk Hong , Lin Heather , Advani Shailesh , Daw Najat , Santiago-O'Farrill Janice , Hollomon Mario , Gordon Nancy B. , Kleinerman Eugenie S.
Published: April 2023

Table S1 show survival analysis for patients with metastatic OS. Table S2 shows LC3B+ puncta in paired specimens. Table S3 shows expression of HMBG1 and SQSTM1 in OS specimens. Table S4 shows the association between biomarkers and histologic treatment response. Table S5 shows pHSP27 expression in OS specimens. Figure S1 shows representative staining of SQSTM1 and HMGB1 in OS. Figures S2-S3 show relapse-free survival based upon biomarker expression. Figure S4 shows survival analysis by LC3B+ amongst patients with poor response to chemotherapy. Figure S5 shows representative staining for pHSP27 in OS.
Supplementary Figure S1-S7 from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Authors: Chen Guangming , Gao Chenxi , Gao Xuan , Zhang Dennis Han , Kuan Shih-Fan , Burns Timothy F. , Hu Jing
Published: April 2023

Supplementary Figure 1: BRAF inhibitor increase nuclear β-catenin in BRAF-mutant CRC cells; Supplementary Figure 2: Wnt/β-catenin pathway activation induced by BRAF inhibitor is dependent on FAK; Supplementary Figure 3: FAK inhibitor synergizes with BRAF inhibitor in the treatment of BRAF-mutant CRC; Supplementary Figure 4: BRAF inhibitor activates FAK and Wnt/β-catenin pathway in patient-derived xenografts (PDX) model; Supplementary Figure 5: Cyclin D1 is induced by BRAF inhibitor through FAK/β-catenin axis; Supplementary Figure 6: BRAF inhibitor combined with FAK inhibitor or β-catenin inhibitor strongly inhibited colony formation; Supplementary Figure 7: Next generation BRAF inhibitors activate FAK and increase cellular level of β-catenin
Supplementary Figure Legends from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Authors: Chen Guangming , Gao Chenxi , Gao Xuan , Zhang Dennis Han , Kuan Shih-Fan , Burns Timothy F. , Hu Jing
Published: April 2023

Figure legends
Supplementary Figures 1-2 from A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies
Authors: Hribar Kolin C. , Wheeler Christopher J. , Bazarov Alexey , Varshneya Kunal , Yamada Ryosuke , Buckley Padraig , Patil Chirag G.
Published: April 2023

Supplementary Figure 1: spheroid growth in VersaGel using tumor cell lines. A) HepG2 hepatocarcinoma cell line; B) LN18 glioblastoma cell line. Scale bar = 1 millimeter. Supplementary Figure 2: VersaGel vs. BME (Matrigel) for Patient 4, Partial Responder (A) and Patient 5, Responder (B).
Supplementary Figure S7 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

Uncropped versions of all western blot membranes
Supplementary Figure S5 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

SPRY2 is not phosphorylated on tyrosine residues in response to 1 treatment. 293 cells were transiently transfected with V5-SPRY2 and treated with 25 μM 1 over a timecourse of up to 90 minutes. Where indicated, cells were treated with FBS (20% v/v) for 15 minutes. Two biological repeats of this experiment were independently conducted.
Table S3 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma
Authors: Feingold Paul L. , Surman Deborah R. , Brown Kate , Xu Yuan , McDuffie Lucas A. , Shukla Vivek , Reardon Emily S. , Crooks Daniel R. , Trepel Jane B. , Lee Sunmin , Lee Min-Jung , Gao Shaojian , Xi Sichuan , McLoughlin Kaitlin C. , Diggs Laurence P. , Beer David G. , Nancarrow Derek J. , Neckers Leonard M. , Davis Jeremy L. , Hoang Chuong D. , Hernandez Jonathan M. , Schrump David S. , Ripley R. Taylor
Published: April 2023

RNAse Esc2 TXNIP
Figure S6 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Authors: Kizilbash Sani H. , Gupta Shiv K. , Chang Kenneth , Kawashima Ryo , Parrish Karen E. , Carlson Brett L. , Bakken Katrina K. , Mladek Ann C. , Schroeder Mark A. , Decker Paul A. , Kitange Gaspar J. , Shen Yuqiao , Feng Ying , Protter Andrew A. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

Evaluation of Ki-67 expression in terminal tumors samples.
Table S1 from Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts
Authors: Noto Fallon K. , Adjan-Steffey Valeriya , Tong Min , Ravichandran Kameswaran , Zhang Wei , Arey Angela , McClain Christopher B. , Ostertag Eric , Mazhar Sahar , Sangodkar Jaya , DiFeo Analisa , Crawford Jack , Narla Goutham , Jamling Tseten Y.
Published: April 2023

ANOVA with multiple comparisons and Tukey's post-hoc test
Table S3 from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

A) Assessment of acute large bowel damage. CD1-nude mice treated with mock treatment or PAN (10 mg/kg) +/-IR. Lesions were scored semi-quantitatively using a 0-5 scale where 0 is no lesion present to 5 where the entire organ was affected by the pathology. B) Assessment of damage to intestine and bladder at 12 weeks. P=lesion present; scoring is semi-quantitative. Cage 2 mouse 1 was culled 2 days after being irradiated in error without the collimator present and cage 2 mouse 5 became unwell 7.5 weeks post-treatment and was culled, but no histopathological effects of the treatment were observed in the bowel. Cage 4 mouse 4 developed moderate diffuse ulcerative colitis. Amyloid was present in the small intestine of animals from all groups including the control group and is considered a pre-existing spontaneous lesion not related to the experimental protocol. Lesions were scored semi-quantitatively using a 0-5 scale where 0 is no lesion present to 5 where the entire organ was affected by the pathology.
Supplementary Table 2 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

Fold induction in secreted cytokine concentrations in PBMC supernatants after IAP antagonist treatment
Supplementary Materials and Methods from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

Preparation of 2-chloro-1-{6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl}ethan-1-one
Table S1 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

LC-MS/MS analysis of lipid metabolites in PDX BL0269
Supplementary Figure 3 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

XIAP antagonism measurements in HEK293-XIAP-Caspase-9 xenografts
Figure S7 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

PTUPB did not increase cisplatin cytotoxicity in the J82, T24 and TCCSUP bladder cancer cell lines
Supplementary Figure 1 from ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Authors: Ward George A. , Lewis Edward J. , Ahn Jong Sook , Johnson Christopher N. , Lyons John F. , Martins Vanessa , Munck Joanne M. , Rich Sharna J. , Smyth Tomoko , Thompson Neil T. , Williams Pamela A. , Wilsher Nicola E. , Wallis Nicola G. , Chessari Gianni
Published: April 2023

IncuCyte images from neutralization of TNF-α activity with anti-TNF-α experiment in MDA-MB-231 cells
Figure S5 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

Histopathological evaluation of major organs
Figure S3 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

Body weight change during PDX bladder cancer mice experiment